Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells

Cancer Medicine

Volumn 4, Issue 4, 2015, Pages 551-564

  Yamashita, Ryo ^a   Sato, Mitsuo ^a   Kakumu, Tomohiko ^a   Hase, Tetsunari ^a   Yogo, Naoyuki ^a   Maruyama, Eiichi ^a   Sekido, Yoshitaka ^a,b   Kondo, Masashi ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Apoptosis; Cell cycle; Epithelial mesenchymal transition; Lung neoplasms; MicroRNAs

Indexed keywords

CISPLATIN; GEMCITABINE; MICRORNA 221; MICRORNA 222; PACLITAXEL; ANTINEOPLASTIC AGENT; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL DIVISION; DRUG EFFECTS; GENETICS; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; S PHASE;

EID: 84984923986     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.412     Document Type: Article

References (35)

1. Olena, A. F., and J. G. Patton 2010. Genomic organization of microRNAs. J. Cell. Physiol. 222:540-545.
2. Shenouda, S. K., and S. K. Alahari 2009. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369-78.
3. Matthias, E., and M. Scherr 2005. MicroRNA and lung cancer. N. Engl. J. Med. 352;23.
4. Bouyssou, J. M., S. Manier, D. Huynh, S. Issa, A. M. Roccaro, and I. M. Ghobrial 2014. Regulation of microRNAs in cancer metastasis. Biochim. Biophys. Acta 1845:255-265.
5. Galardi, S., N. Mercatelli, E. Giorda, S. Massalini, G. V. Frajese, S. A. Ciafre, et al. 2007. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282:23716-23724.
6. Felli, N., L. Fontana, E. Pelosi, R. Botta, D. Bonci, F. Facchiano, et al. 2005. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. USA 102:18081-18086.
7. Ciafre, S. A., S. Galardi, A. Mangiola, M. Ferracin, C. G. Liu, G. Sabatino, et al. 2005. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334:1351-1358.
8. Rounak Nassirpour, P. P. M., S. M. Baxi, and M.-J. Yin 2013. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 8:e62170.
9. Stinson, S., M. R. Lackner, A. T. Adai, N. Yu, H. J. Kim, C. O'Brien, et al. 2011. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signal. 4:ra41.
10. Howe, E. N., D. R. Cochrane, and J. K. Richer 2012. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J. Mammary Gland Biol. Neoplasia 17:65-77.
11. Fornari, F., L. Gramantieri, M. Ferracin, A. Veronese, S. Sabbioni, G. A. Calin, et al. 2008. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27:5651-5661.
12. Kim, Y. K., J. Yu, T. S. Han, S. Y. Park, B. Namkoong, D. H. Kim, et al. 2009. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 37:1672-1681.
13. Medina, R., S. K. Zaidi, C. G. Liu, J. L. Stein, A. J. van Wijnen, C. M. Croce, et al. 2008. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 68:2773-2780.
14. O'Hara, A. J., L. Wang, B. J. Dezube, W. J. Harrington Jr, B. Damania, and D. P. Dittmer 2009. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 113:5938-5941.
15. Okamoto, K., K. Miyoshi, and Y. Murawaki 2013. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS ONE 8:e77623.
16. Garofalo, M., G. Di Leva, G. Romano, G. Nuovo, S. S. Suh, A. Ngankeu, et al. 2009. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16:498-509.
17. Larsen, J. E., and J. D. Minna 2011. Molecular biology of lung cancer: clinical implications. Clin. Chest Med. 32:703-740.
18. Sato, M., D. S. Shames, A. F. Gazdar, and J. D. Minna 2007. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2:327-343.
19. Gandhi, J., J. Zhang, Y. Xie, J. Soh, H. Shigematsu, W. Zhang, et al. 2009. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 4:e4576.
20. Ramirez, R. D., S. Sheridan, L. Girard, M. Sato, Y. Kim, J. Pollack, et al. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64:9027-9034.
21. Sato, M., J. E. Larsen, W. Lee, H. Sun, D. S. Shames, M. P. Dalvi, et al. 2013. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol. Cancer Res. 11:638-650.
22. Sato, M., M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, et al. 2006. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66:2116-2128.
23. Takeyama, Y., M. Sato, M. Horio, T. Hase, K. Yoshida, T. Yokoyama, et al. 2010. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 296:216-224.
24. Horio, M., M. Sato, Y. Takeyama, M. Elshazley, R. Yamashita, T. Hase, et al. 2011. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells. Ann. Surg. Oncol. 19(Suppl. 3):S634-S645.
25. Elshazley, M., M. Sato, T. Hase, R. Yamashita, K. Yoshida, S. Toyokuni, et al. 2012. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int. J. Cancer 131:2820-2831.
26. Hase, T., M. Sato, K. Yoshida, L. Girard, Y. Takeyama, M. Horio, et al. 2011. Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer Sci. 102:1493-1500.
27. Tiwari, N., A. Gheldof, M. Tatari, and G. Christofori 2012. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol. 22:194-207.
28. da Huang, W., B. T. Sherman, and R. A. Lempicki 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
29. da Huang, W., B. T. Sherman, and R. A. Lempicki 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1-13.
30. Kneitz, B., M. Krebs, C. Kalogirou, M. Schubert, S. Joniau, vanPoppel H., et al. 2014. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 74:2591-603.
31. Smith, J., L. M. Tho, N. Xu, and D. A. Gillespie 2010. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108:73-112.
32. Ivashkevich, A., C. E. Redon, A. J. Nakamura, R. F. Martin, and O. A. Martin 2012. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 327:123-133.
33. Bonner, W. M., C. E. Redon, J. S. Dickey, A. J. Nakamura, O. A. Sedelnikova, S. Solier, et al. 2008. GammaH2AX and cancer. Nat. Rev. Cancer 8:957-967.
34. Azzoli, C. G., S. Temin, and G. Giaccone 2012. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Oncol. Pract. 8:63-66.
35. Garofalo, M., C. Quintavalle, G. Di Leva, C. Zanca, G. Romano, C. Taccioli, et al. 2008. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27:3845-3855.